New trial of Genmab substance is symptomatic of Deborah Dunsire's Lundbeck

The study involving the Lu AF82422 antibody illustrates several of Lundbeck's recent tendencies, including attempts to ensure a higher study success rate and more substances in the company pipeline. This goes for both the approach to development and the variety of substances.
Since Deborah Dunsire joined Lunbeck three years ago, she has been hard at work getting the success rate of the company's research and development efforts back on track. | Photo: Gregers Tycho/ERH
Since Deborah Dunsire joined Lunbeck three years ago, she has been hard at work getting the success rate of the company's research and development efforts back on track. | Photo: Gregers Tycho/ERH
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

The newly announced phase II trial with the substance Lu AF82422, which is part of a collaboration between Genmab and Lundbeck, is in many ways an example of the new research strategy that Lundbeck has created under the leadership of CEO Deborah Dunsire and Head of Research and Development Johan Luthman.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading